A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Metastatic Colorectal Cancer
Related studies linked through entity extraction aliases.
Circulating Tumor Cells in mCRC for Liver Resection
- Status
- UNKNOWN
- Phase
- N/A
Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer
- Status
- UNKNOWN
- Phase
- N/A
Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen
- Status
- COMPLETED
- Phase
- PHASE2
Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies
- Status
- COMPLETED
- Phase
- PHASE2
Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
- Status
- COMPLETED
- Phase
- PHASE1
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO)
- Status
- UNKNOWN
- Phase
- N/A
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
- Status
- COMPLETED
- Phase
- PHASE1
First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS
- Status
- COMPLETED
- Phase
- PHASE3
Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
- Status
- WITHDRAWN
- Phase
- PHASE2
The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patients
- Status
- UNKNOWN
- Phase
- PHASE2
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2